At this time of year, and more so than ever as a result of the global pandemic, many families have come to rely on charitable donations and the generosity of volunteers to have access to basic provisions. In the UK, more than 14 million people are living in poverty – including 4.5 million children. As…
Investors in People Silver accreditation acknowledges that PHARMExcel has been awarded one of the highest levels of accreditation within the Investors in People framework. The Silver accreditation is usually awarded to the top 5% of organisations assessed.
PHARMExcel are delighted to have be selected as INmuneBio’s U.K. CRO to lead on their Phase I clinical trial of INKmune, a novel therapy to prime the patient’s own Natural Killer (NK) cells to attack their cancer, in patients with high-risk Myelodysplastic Syndrome (MDS) (EUDRACT 2019-004820-40). This is a single center, Phase I trial and will…
BACKGROUND PHARMExcel was selected to manage a UK, Phase II, combined Investigational Medicinal Product (IMP)/Medical Device study for COVID-19 patients hospitalised in ICU. We were asked to provide Project Management (PM), Monitoring and Safety oversight for the study, from protocol development to close-out. The study involved two sites and numerous teams responsible for key elements…
Below is a small interview held with Mike Ring, one of our Study/Project Managers, who gives us a glimpse into his day at PHARMExcel What’s a typical day for you? Although it may sound cliché, there really is no such thing as a typical day here at PHARMExcel! This is a true hybrid role in…
PHARMExcel are delighted to be involved in delivering a Covid 19 study in collaboration with Southampton University. We are facilitating fast track approvals and delivery, aiming for site activation by the end of May
© Copyright 2023 PHARMExcel | Website by Union 10 Design
